ARS Pharmaceuticals (SPRY) Common Equity (2020 - 2026)

ARS Pharmaceuticals has reported Common Equity for 7 years, with the latest figure at $61.3 million in Q1 2026.

• Quarterly Common Equity fell 73.22% year-over-year to $61.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.3 million (down 73.22% YoY) and the FY2025 annual result came in at $114.3 million, down 55.51% from the prior year.
• Common Equity declined to $61.3 million in Q1 2026 per SPRY's latest filing, from $114.3 million in the prior quarter.
• Over five years, Common Equity peaked at $272.9 million in Q4 2022 and troughed at -$50.2 million in Q3 2022.
• A 5-year average of $162.3 million and a median of $215.2 million in 2024 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 972.7% in 2022, down 115.1% in 2022.
• Over 5 years, Common Equity stood at $272.9 million in 2022, then slipped by 15.44% to $230.8 million in 2023, then grew by 11.28% to $256.8 million in 2024, then sank by 55.51% to $114.3 million in 2025, then sank by 46.34% to $61.3 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $61.3 million, $114.3 million, and $147.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.